Chernobyl, the largest ever nuclear accident, caused a huge release of radioactive isotopes, including nearly 2x10(18) Bq of iodine-131. Four years later an increase in thyroid cancer incidence, virtually all papillary carcinomas in children, occurred in the highly exposed areas. The increase has continued, and with increasing latency the tumour molecular and morphological pathology has changed; further changes may occur in the future. Children under the age of 1 at exposure show the highest susceptibility, and carry this risk with them into adult life; 4000 cases have been attributed to the accident, but so far very few have died. The risk falls rapidly with increasing age at exposure; it is doubtful if there is any risk for adults at exposure. Other factors linked to susceptibility to thyroid carcinogenesis after Chernobyl include dose, iodine deficiency, and genetic factors. Other consequences are briefly covered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.beem.2008.09.020 | DOI Listing |
J Surg Res
January 2025
Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri.
Background: Radioactive iodine (RAI) is a common treatment for various thyroid diseases. Previous studies have suggested susceptibility of parathyroid glands to the mutagenic effect of RAI and the development of primary hyperparathyroidism (PHPT). We tested the possible link between prior RAI treatment, disease presentation, and treatment outcomes.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
Breast Surgery, Kyoto University Graduate School of Medicine, Shogoin Sakyo-ku, Kyoto, Japan.
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
January 2025
Department of Pediatric Oncology, Faculty of Medicine, Ege University.
Background: This study aims to establish the characteristics of second primary neoplasms (SPNs) and the long-term follow-up status of a tertiary pediatric oncology center.
Methods: Records of 1799 patients followed up in the pediatric oncology division between January 1981 and December 2022 were evaluated retrospectively.
Results: Thirty-four (1.
Curr Oncol
January 2025
Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival.
View Article and Find Full Text PDFBioengineering (Basel)
December 2024
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94115, USA.
In exploring adjuvant therapies for head and neck cancer, hyperthermia (40-45 °C) has shown efficacy in enhancing chemotherapy and radiation, as well as the delivery of liposomal drugs. Current hyperthermia treatments, however, struggle to reach large deep tumors uniformly and non-invasively. This study investigates the feasibility of delivering targeted uniform hyperthermia deep into the tissue using a non-invasive ultrasound spherical random phased array transducer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!